Eli Lilly is leading the market for GLP-1 medications (for weight loss and diabetes). In a decade, Eli Lilly could be in the ...

Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Dec 11 (Reuters) - Eli Lilly said on Thursday its ‌next-generation ​obesity drug helped patients lose ‌an average of 28.7% of ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

Seeking Alpha's roundup of statements, announcements, and remarks that could impact markets, sectors, or individual stocks.

With a market capitalization approaching the $1 trillion mark, Eli Lilly is engaged in a close competitive race with Novo Nordisk for dominance in the obesity treatment sector. Market researchers ...

Important state and national stories, market and business news, sports and entertainment, delivered in quick-hit fashion ...

Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...

Northwell Health reports that "Ozempic face" describes the facial changes from rapid weight loss using Ozempic, highlighting ...

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal ...

Target expands protein and supplement offerings as appetite-suppressing weight-loss drugs change consumer habits.